| Corey R Smith, DO | |
|
2605 Willow Street Pike N, Willow Street, PA 17584-9510 | |
| (717) 464-2838 | |
| (717) 464-3812 |
| Full Name | Corey R Smith |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 27 Years |
| Location | 2605 Willow Street Pike N, Willow Street, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750324679 | NPI | - | NPPES |
| 100951404 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | OS010015-L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lancaster General Hospital | Lancaster, PA | Hospital |
| St Joseph Medical Center | Reading, PA | Hospital |
| Heart Of Lancaster Regional Medical Center | Lititz, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lancaster General Medical Group | 0941103683 | 463 |
| Penn State Health Community Medical Group Llc | 8729351077 | 646 |
News Archive
University of Florida radiation oncologists are using a sophisticated medical device to treat patients who have recent diagnoses of metastatic cancer, where the disease has started to spread from one part of the body to another.
iCo Therapeutics Inc. today reported financial results for the three months ended September 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).
A new study describes some potentially important genetic factors in the host that may shape the clinical symptoms and signs of the disease.
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"), for the treatment of hepatitis C virus infection ("HCV").
› Verified 8 days ago
| Entity Name | Lancaster General Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952392383 PECOS PAC ID: 0941103683 Enrollment ID: O20040309000916 |
News Archive
University of Florida radiation oncologists are using a sophisticated medical device to treat patients who have recent diagnoses of metastatic cancer, where the disease has started to spread from one part of the body to another.
iCo Therapeutics Inc. today reported financial results for the three months ended September 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).
A new study describes some potentially important genetic factors in the host that may shape the clinical symptoms and signs of the disease.
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"), for the treatment of hepatitis C virus infection ("HCV").
› Verified 8 days ago
| Entity Name | Penn State Health Community Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861988644 PECOS PAC ID: 8729351077 Enrollment ID: O20170907002279 |
News Archive
University of Florida radiation oncologists are using a sophisticated medical device to treat patients who have recent diagnoses of metastatic cancer, where the disease has started to spread from one part of the body to another.
iCo Therapeutics Inc. today reported financial results for the three months ended September 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).
A new study describes some potentially important genetic factors in the host that may shape the clinical symptoms and signs of the disease.
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"), for the treatment of hepatitis C virus infection ("HCV").
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Corey R Smith, DO 2605 Willow Street Pike N, Willow Street, PA 17584-9510 Ph: (717) 464-2838 | Corey R Smith, DO 2605 Willow Street Pike N, Willow Street, PA 17584-9510 Ph: (717) 464-2838 |
News Archive
University of Florida radiation oncologists are using a sophisticated medical device to treat patients who have recent diagnoses of metastatic cancer, where the disease has started to spread from one part of the body to another.
iCo Therapeutics Inc. today reported financial results for the three months ended September 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).
A new study describes some potentially important genetic factors in the host that may shape the clinical symptoms and signs of the disease.
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"), for the treatment of hepatitis C virus infection ("HCV").
› Verified 8 days ago
Lynn Ma, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 2605 Willow Street Pike N, Willow Street, PA 17584 Phone: 717-464-2838 | |
John J Schmitt, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2850 Willow Street Pike N, Suite A, Willow Street, PA 17584 Phone: 717-464-9430 Fax: 717-464-1680 | |
Leanne K Beidler, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 222 Willow Valley Lakes Dr Ste 400, Willow Street, PA 17584 Phone: 717-544-8694 Fax: 717-544-8695 | |
Robert K Aichele Jr., DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2605 Willow Street Pike, Willow Street, PA 17584 Phone: 717-464-2838 | |
Daniel Lee Diehl, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2605 Willow Street Pike N, Willow Street, PA 17584 Phone: 717-464-2838 Fax: 717-464-3812 | |
Marina Gonzalez, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 222 Willow Valley Lakes Dr Ste 1900, Willow Street, PA 17584 Phone: 717-517-5350 Fax: 717-517-5351 | |
Eli J Wayman, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 222 Willow Valley Lakes Dr Ste 1900, Willow Street, PA 17584 Phone: 717-517-5350 Fax: 717-517-5351 |